Finder's Pick for
Beginners

AbbVie is a drug manufacturers-general business based in the US. AbbVie stocks (ABBV.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $152.5 – an increase of 10.17% over the previous week. AbbVie employs 50,000 staff and has a trailing 12-month revenue of around $56.7 billion.
Finder's Pick for
Beginners
Finder's Pick for
Global Trading
Finder's Pick for
Commodity Stocks
Finder's Pick for
Free Trades
Latest market close | $152.34 |
---|---|
52-week range | $102.35 - $174.43 |
50-day moving average | $150.67 |
200-day moving average | $135.51 |
Wall St. target price | $163.01 |
PE ratio | 21.4388 |
Dividend yield | $5.42 (4.08%) |
Earnings per share (TTM) | $6.97 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $152.34 from 2022-06-24
1 week (2022-06-17) | 10.17% |
---|---|
1 month (2022-05-23) | 2.91% |
3 months (2022-03-21) | N/A |
6 months (2021-12-21) | N/A |
1 year (2021-06-25) | 34.84% |
---|---|
2 years (2020-06-25) | 57.07% |
3 years (2019-06-25) | 131.87% |
5 years (2017-06-23) | 109.72% |
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, AbbVie shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2788. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $28.4 billion.
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $56.7 billion |
---|---|
Operating margin TTM | 35.41% |
Gross profit TTM | $38.9 billion |
Return on assets TTM | 8.55% |
Return on equity TTM | 83.12% |
Profit margin | 22% |
Book value | $9.22 |
Market capitalisation | $264.1 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 01/01/2019) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
Dividend payout ratio: 41.98% of net profits
Recently AbbVie has paid out, on average, around 41.98% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.08% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 4.08% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $5.42 per share.
While AbbVie's payout ratio might seem fairly standard, it's worth remembering that AbbVie may be investing much of the rest of its net profits in future growth.
AbbVie's most recent dividend payout was on 16 May 2022. The latest dividend was paid out to all shareholders who bought their shares by 14 April 2022 (the "ex-dividend date").
Over the last 12 months, AbbVie's shares have ranged in value from as little as $102.3545 up to $174.4275. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.8113. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc.
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Read more…Here are some investment ideas that could do well despite rising interest rates.
Read more…iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PXE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing FCG stock, with 24-hour and historical pricing before you buy.